Literature DB >> 22818513

Risk for prescription opioid misuse among patients with a history of substance use disorder.

Benjamin J Morasco1, Dennis C Turk, Dennis M Donovan, Steven K Dobscha.   

Abstract

BACKGROUND: History of substance use disorder (SUD) is associated with risk for prescription opioid misuse in chronic pain patients; however, little data are available regarding risk for prescription opioid misuse within the subgroup of patients with SUD histories.
METHODS: Participants with chronic pain, histories of SUD, and current opioid prescriptions were recruited from a single VA Medical Center. Participants (n=80) completed measures of risk for prescription opioid misuse, pain severity, pain-related interference, pain catastrophizing, attitudes about managing pain, emotional functioning, and substance abuse.
RESULTS: Participants were divided into three groups based on risk for prescription opioid misuse, as assessed by the Pain Medication Questionnaire (PMQ). Participants in the High-PMQ group reported more pain severity, interference, catastrophizing, depressive symptoms, and lowest self-efficacy for managing pain, relative to the Low-PMQ group; the High-PMQ group and Moderate-PMQ group differed on measures of pain severity, catastrophizing, and psychiatric symptoms (all p-values <0.05). The High-PMQ group had the highest rates of current SUD (32% versus 20% and 0, p=0.009). A regression analysis evaluated factors associated with PMQ scores: pain catastrophizing was the only variable significantly associated with risk for prescription opioid misuse.
CONCLUSIONS: Among patients with SUD histories, those with higher risk for prescription opioid misuse reported more pain and impairment, symptoms of depression, and were more likely to have current SUD, relative to patients with lower risk for prescription opioid misuse. In adjusted analyses, pain catastrophizing was significantly associated with risk for prescription opioid misuse, but current SUD status was not a significant predictor. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22818513      PMCID: PMC3484237          DOI: 10.1016/j.drugalcdep.2012.06.032

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  44 in total

Review 1.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

2.  The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain.

Authors:  Stephen M Wu; Peggy Compton; Roger Bolus; Beatrix Schieffer; Quynh Pham; Ariel Baria; Walter Van Vort; Frederick Davis; Paul Shekelle; Bruce D Naliboff
Journal:  J Pain Symptom Manage       Date:  2006-10       Impact factor: 3.612

3.  Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.

Authors:  Marilyn S Huckans; Aaron D Blackwell; Todd A Harms; David W Indest; Peter Hauser
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

4.  Pain medication beliefs and medication misuse in chronic pain.

Authors:  Beatrix M Schieffer; Quyhn Pham; Jennifer Labus; Ariel Baria; Walter Van Vort; Philip Davis; Frederick Davis; Bruce D Naliboff
Journal:  J Pain       Date:  2005-09       Impact factor: 5.820

5.  Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.

Authors:  Lynn R Webster; Rebecca M Webster
Journal:  Pain Med       Date:  2005 Nov-Dec       Impact factor: 3.750

6.  Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse.

Authors:  Steven D Passik; Kenneth L Kirsh; Kathleen B Donaghy; Russell K Portenoy
Journal:  Clin J Pain       Date:  2006-02       Impact factor: 3.442

7.  An opioid screening instrument: long-term evaluation of the utility of the Pain Medication Questionnaire.

Authors:  Cara P Holmes; Robert J Gatchel; Laura L Adams; Anna W Stowell; Alyson Hatten; Carl Noe; Leland Lou
Journal:  Pain Pract       Date:  2006-06       Impact factor: 3.183

8.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

9.  Development and initial validation of a scale to measure self-efficacy beliefs in patients with chronic pain.

Authors:  Karen O Anderson; Barbara Noel Dowds; Robyn E Pelletz; Thomas W Edwards; Christine Peeters-Asdourian
Journal:  Pain       Date:  1995-10       Impact factor: 6.961

10.  Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.

Authors:  Timothy J Ives; Paul R Chelminski; Catherine A Hammett-Stabler; Robert M Malone; J Stephen Perhac; Nicholas M Potisek; Betsy Bryant Shilliday; Darren A DeWalt; Michael P Pignone
Journal:  BMC Health Serv Res       Date:  2006-04-04       Impact factor: 2.655

View more
  32 in total

Review 1.  The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward?

Authors:  Patrick H Finan; Bethany Remeniuk; Kelly E Dunn
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-08-01       Impact factor: 5.067

2.  Negative Affect-Related Factors Have the Strongest Association with Prescription Opioid Misuse in a Cross-Sectional Cohort of Patients with Chronic Pain.

Authors:  Gadi Gilam; John A Sturgeon; Dokyoung S You; Ajay D Wasan; Beth D Darnall; Sean C Mackey
Journal:  Pain Med       Date:  2020-02-01       Impact factor: 3.750

3.  Pain Catastrophizing Moderates Relationships between Pain Intensity and Opioid Prescription: Nonlinear Sex Differences Revealed Using a Learning Health System.

Authors:  Yasamin Sharifzadeh; Ming-Chih Kao; John A Sturgeon; Thomas J Rico; Sean Mackey; Beth D Darnall
Journal:  Anesthesiology       Date:  2017-07       Impact factor: 7.892

Review 4.  Opioid Use Disorders: Perioperative Management of a Special Population.

Authors:  Emine Nalan Ward; Aurora Naa-Afoley Quaye; Timothy E Wilens
Journal:  Anesth Analg       Date:  2018-08       Impact factor: 5.108

5.  Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis.

Authors:  Patrick H Finan; C Patrick Carroll; Gyasi Moscou-Jackson; Marc O Martel; Claudia M Campbell; Alex Pressman; Joshua M Smyth; Jean-Michel Tremblay; Sophie M Lanzkron; Jennifer A Haythornthwaite
Journal:  J Pain       Date:  2017-09-21       Impact factor: 5.820

6.  Is employment status in adults over 25 years old associated with nonmedical prescription opioid and stimulant use?

Authors:  Alexander S Perlmutter; Sarah C Conner; Mirko Savone; June H Kim; Luis E Segura; Silvia S Martins
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-11-17       Impact factor: 4.328

7.  The association between catastrophizing and craving in patients with chronic pain prescribed opioid therapy: a preliminary analysis.

Authors:  Marc O Martel; Robert N Jamison; Ajay D Wasan; Robert R Edwards
Journal:  Pain Med       Date:  2014-03-10       Impact factor: 3.750

8.  Predictors of Daily Pain Medication Use in Individuals with Recurrent Back Pain.

Authors:  John A Sturgeon; Jennifer M Hah; Yasamin Sharifzadeh; Stephanie K Middleton; Thomas Rico; Kevin A Johnson; Sean C Mackey
Journal:  Int J Behav Med       Date:  2018-04

9.  Catastrophic thinking and increased risk for prescription opioid misuse in patients with chronic pain.

Authors:  M O Martel; A D Wasan; R N Jamison; R R Edwards
Journal:  Drug Alcohol Depend       Date:  2013-04-22       Impact factor: 4.492

10.  The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality.

Authors:  Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Amy C Justice; David A Fiellin
Journal:  J Addict Med       Date:  2016 Nov/Dec       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.